KemPharm/$ZVRA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About KemPharm

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Ticker

$ZVRA
Sector
Health
Primary listing
NASDAQ

Employees

59
Headquarters
Celebration, United States
Website
zevra.com

KemPharm Metrics

BasicAdvanced
$495M
16.39
$0.54
-
-

What the Analysts think about KemPharm

Analyst ratings (Buy, Hold, Sell) for KemPharm stock.

Bulls say / Bears say

Net revenue surged to $25.9 million in Q2 2025, with MIPLYFFA accounting for $21.5 million of that total, underscoring rapid market uptake and sixfold year-over-year growth for the product. (Globe Newswire)
Zevra closed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million in non-dilutive capital, significantly bolstering the balance sheet to support commercial launches and pipeline advancement. (Globe Newswire)
The Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome enrolled 39 patients as of June 30, 2025, demonstrating steady clinical progress toward addressing a high-unmet-need indication. (SEC Filing)
OLPRUVA underperformed in Q2 2025 with just $0.3 million in net revenue and only one new prescription enrollment, despite achieving 79% market access, highlighting slow commercial adoption of the therapy. (Globe Newswire)
The company recognized a $58.7 million non-cash impairment charge on OLPRUVA intangible assets and an $11.7 million inventory obsolescence expense in Q2 2025, reflecting material write-downs of the asset’s value. (Globe Newswire)
SG&A expenses jumped to $20.8 million in Q2 2025, a year-over-year increase of $8.2 million, which could pressure operating margins as the company scales its commercial infrastructure. (Globe Newswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.

KemPharm Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KemPharm Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZVRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs